Company: ENTXW
Filing Date: 2025-01-10
Form Type: 424B5
Source: 0001178913-25-000079
Chunk: 6

Company: Entera Bio Ltd.
Filing Date: 2025-01-10
Form: 424B5
Chunk 6
---
 by us to achieve a publicly announced milestone; |

| • | delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products; |

| • | changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; |

| • | changes in our expenditures to promote our products; |

| • | variance in our financial performance from the expectations of market analysts; |

| • | the limited trading volume of our ordinary shares; and |

| • | general economic and market conditions, including factors unrelated to our industry or operating performance. |

In addition, the stock market in general has recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market and industry factors may materially affect the market price of companies’ stock, including ours, regardless of actual operating performance. Future sales of our ordinary shares, other securities convertible into our ordinary shares or preferred shares could cause the market value of our ordinary shares to decline and could result in dilution of your shares. We may issue up to 30,000,000 of our ordinary shares as part of the offering contemplated by this prospectus supplement and the accompanying prospectus. In addition, our board of directors is authorized, without your approval, to cause us to issue additional shares of our ordinary shares or to raise capital through the issuance of debt securities convertible into ordinary shares, options, warrants and other rights, on terms and for consideration as our board of directors in its sole discretion may determine. Sales of substantial amounts of our ordinary shares could cause the market price of our ordinary shares to decrease significantly. We cannot predict the effect, if any, of future sales of our ordinary shares, or the availability of our ordinary shares for future sales, on the value of our ordinary shares. Sales of substantial amounts of our ordinary shares by our directors or officers or another large shareholder, or the perception that such sales could occur, may adversely affect the market price of our ordinary shares. S - 4 There is a risk that we may be a passive foreign investment company, for U.S. federal income tax purposes for any taxable year, which generally would result in certain adverse U.S. federal income tax consequences to our U.S. investors. There is a risk that we may be treated as a passive foreign investment company, or PFIC, for any taxable year. The application of the PFIC rules to a company like us is subject to uncertainties, and for the reasons described below, we cannot express a